Drugs / Recombinant Mycobacterium Tuberculosis Fusion Protein Tuberculin Skin Test
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07587164 | May → Aug 2025 | latent tuberculosis infection | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Mycobacterium Tuberculosis Fusion Protein Tuberculin Skin Test | “Recombinant Mycobacterium Tuberculosis Fusion Protein Tuberculin Skin Test (C-TST)” NCT07587164 ↗ |
| Known as | C-TST | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07587164 ↗ |
| Modality | Diagnostic / imaging agent | “C-TST for Diagnosis of Latent Mycobacterium Tuberculosis Infection in Indonesia” NCT07587164 ↗ |